Abstract
This study was designed to determine biochemical and pharmacological properties of a newly synthesized benzimidazole derivative, 2-amino-4,5-dihydropyrido [1,2-a] thiazolo [5,4-g] benzimidazole (YJA20379-5)in vitro andin vivo. In the leaky membrane vesicles of pig gastric mucosa, YJA20379-5 inhibited the K+-stimulated H+,K+-ATPase activity in a concentration- and time-dependent manner, with IC50 values being 43 μM and 31 μM at pH 6.4 and 7.4, respectively. YJA20379-5, given intraduodenally, had a potent inhibitory effect on the gastric acid secretion in pylorus-ligated rats. The ED50 value for acid secretion was 15.4 mg/kg. YJA20379-5, administered orally, also suppressed gastric damages induced by water-immersion stress, indomethacin and ethanol, and duodenal damage induced by mepirizole in rats; the ED50 values were 17.6, 4.7, 3.0 and 18.7 mg/kg, respectively. Furthermore, repeated oral administration of YJA20379-5 accelerated the spontaneous healing of acetic acid-induced gastric ulcers in rats. It is concluded that the antisecretory activity of YJA20379-5 appears to be associated with inhibition of H+,K+-ATPase, while its antigastric and antiduodenal lesion activities are primarily related to the antisecretory effect.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References Cited
Elander, B., Fellenius, E., Leth, R., Olbe, L. and Wallmark, B., Inhibitory action of omeprazole on acid formation in gastric glands and on H+, K+-ATPase isolated from human gastric mucosa.Scand. J. Gastroenterol., 21, 268–272 (1986).
Caldwell, S. H. and McCallum, R. W., Handbook of Experimental Pharmacology, In Clollen, M. J. and Benjamin, S. B. (Eds.),Hypothesis of peptic disease. Springer-Verlag, Berlin Heidelberg, pp. 189–227, 1991.
Classen, M., Damman, H. G., Domschke, W., Huttemannm, W., Longdong, W., Rehner, M., Simon, B., Witzel, L. and Berger, J., Omeprazole heals duodenal, but not gastric ulcers more rapidly than ranitidine.Hepatogastroenterology, 32, 243–245 (1985).
Dixon, M. and Webb, E. C., Enzymes, 3rd Ed., Longman, London, 1979.
Fellinius, E., Berglindh, T., Sachs, G., Olbe, L., Elander, B., Sjostrand, S. E., Wallmark, B., Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+,K+)-ATPase.Nature, 290, 159–161 (1981).
Finney, D. J.,Probit analysis, 3rd Ed, Cambridge University Press, Cambridge, 1971.
Fiske, C. H. and Subbarow, Y., The colorimetric determination of phosphorous.J. Biol. Chem., 66, 375–400 (1924).
Hirschowitz, B. I., Keeling, D., Lewin, M., Okabe, S., Parsons, M., Sewing, K., Wallmark, B. and Sachs, G., Pharmacological aspects of acid secretion.Dig. Dis. Sci., 40, (Suppl. 2), 3s-23s (1995).
Hioki, Y., Takada, J., Hidaka, Y., Takeshita, H., Hosoi, M. and Yano, M., A newly synthesized pyridine derivative, (Z)-5-methyl-2-[2-(1-naphthyl)ethenyl]-4-prperidinopyridine hydrochloride (AU-1421), as a reversible gastric proton pump inhibitor.Arch. int. Pharmacodyn., 305, 32–44 (1990).
LaMattina, J. L., McCarthy, P. A., Reiter, L. A., Holt, W. F., and Yeh, L. A., Antiulcer agents. 4-Substituted 2-guanidinothiazoles: reversible, competitive, and selective inhibitors of gastric H+,K+-ATPase.J. Med. Chem., 33, 543–552 (1990).
Lowry, O. H., Rosebrough, N. J., Farr, A. L. and Randall, R. J., Protein measurement with the Folin phenol reagent.J. Biol. Chem., 193, 265–275 (1951).
Reenstra, W. W., Bettencourt, J. D. and Forte, J. G., Kinetic studies of the gastric H+,K+-ATPase.J. Biol. Chem., 263, 19618–19625 (1985).
Saccomani, G., Stewart, H. B., Shaw, D., Lewin, M. and Sachs, G., Characetrization of gastric mucosal menbranes. IX. Fractionation and purifiation of K+-ATPase containing vesicles by zonal centrifugation and free-flow electrophoresis technique.Biochim. Biophys. Acta. 465, 311–330 (1977).
Sachs, G., Chang, H. H., Rabon, E., Schackman, R., Lewin, M. and Saccomani, G., A nonelectrogenic H+ pump in plasma membranes of hog stomach.J. Biol. Chem., 251, 7690–7698 (1976).
Shay, M., Sun, O. C. H. and Gruenstein, M., A quantitative method for measuring spontanous gastric secretion in the rat.Gastroenterology, 26, 906–913 (1954).
Tanaka, H., Taqkeuchi, K., Okabe, S. and Murakami, M., Pathogenesis of the earliest epithelial cell damage induced by mepirizole and cysteamine in the rat duodenum.Jpn. J. Pharmacol., 51, 509–519 (1989).
Tytgat, G. N., Lamers, C. B., Hameeteman, W., Jansen, J. M. and Wilson, J. A., Omeprazole in peptic ulcers resistant to histamine H2-receptor antagonists.Aliment. Pharmacol. Ther., 1, 31–38 (1987).
Wallmark, B., Brandstrom, A. and Larsson, H., Evidence for acid-induced transformation of omeprazole into an active inhibitor of H+,K+-ATPase within the parietal cell.Biochim. Biophys. Acta, 778, 549–558 (1984).
Wallmark, B., Larsson, H.,and Humble, L., The relationship between gastric acid secretion and gastric H+,K+-ATPase activity.J. Biol. Chem., 260, 13681–13684 (1985).
Yamada, M., Yura, T., Morimoto, M., Harada, T., Yamada, K., Honma, Y., Kinsoshita, M. and Sugiura, M., 2[(2-Aminobenzy)sulfinyl]-1-(2-pyridyl)-1,4,5,6-tetrahydro cyclopent[d]imidazoles as a novel class of gastric H+,K+-ATPase inhibitor.J. Med. Chem., 39, 596–604 (1996).
Yamamoto, O., Okada, Y. and Okabe, S., Effects of a proton pump inhibitor, omeprazole, on gastric secretion and gastric and duodenal ulcers or erosions in rats.Dig. Dis. Sci., 29, 394–401 (1984).
Yuki, H., Kamato, T., Nishida, A., Ohta, M., Shikama, H., Yanagisawa, I. and Miyata, K., Antisecretory and antiulcer effects of YM020, a new H+,K+-AT-Pase inhibitor, in rats and dogs.Jpn. J. Pharmacol., 67, 59–67 (1995).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Shon, S.K., Chang, M.S., Chung, Y.K. et al. Biochemical and pharmacological properties of a new proton pump inhibitor, 2-amino-4,5-dihydropyrido[1,2-a]thiazolo [5,4-g] benzimidazole (YJA20379-5). Arch. Pharm. Res. 21, 241–247 (1998). https://doi.org/10.1007/BF02975282
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02975282